Expressions of CD68, Bcl-2 and VEGF165 in breast cancer and their clinical significance

doi:10.3877/cma. j. issn.1674-0807.2014.02.008

Abstract

Abstract:

Objective

To explore the expressions of CD68, B cell lymphoma/leukemia-2(Bcl-2) and VEGF165 in breast cancer tissue and their clinical significance.

Methods

We collected the surgically resected specimens from 40 cases of invasive breast cancer from March 2012 to March 2013 in our hospital. The expressions of CD68, Bcl-2 and VEGF165 were detected by immunohistochemistry in breast cancer tissue and adjacent normal tissue of the 40 cases. Measurement data was processed using one-way ANOVA, numeration data using the chi-square test or Fisher’s exact method. Correlation analysis was performed using Pearson correlation analysis.

Results

The positive expression rates of CD68, Bcl-2 and VEGF165 were 70.0% (28/40),77.5% (31/40), 80.0% (32/40) in breast cancer tissue, and 10% (4/40), 57.5% (23/40),15.0% (6/40) in adjacent tissues respectively, suggesting that the difference was statistically significant (t=20.637,21.877,35.104, all P=0.000) . The expressions of CD68, Bcl-2 and VEGF165 in invasive breast cancer tissue were not correlated with the patient’s age, vascular invasion, ER and PR expression, but correlated with TNM stage (r=4.571,4.167,4.167, P=0.033, 0.041, 0.041) and lymph node metastasis(r=8.127, P=0.004; χ²=5.974, P=0.015; P=0.036). Pearson linear correlation analysis showed that in breast cancer tissue,there was a positive correlation between Bcl-2 and CD68 (r=0.793,P=0.000),between CD68 and VEGF165 (r=0.494, P=0.002), and between Bcl-2 and VEGF165 (r=0.507, P=0.001).

Conclusion

CD68, Bcl-2 and VEGF165 are over-expressed in breast cancer tissue, which can provide references to the evaluation of breast cancer.

Key words: Breast neoplasms, Vascular endothelial growth factors, Macrophages, Genes, bcl-2, CD68

Jie An, Wei Liu, Shuang Liu. Expressions of CD68, Bcl-2 and VEGF165 in breast cancer and their clinical significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2014, 08(02): 109-113.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma. j. issn.1674-0807.2014.02.008

https://zhrxbzz.cma-cmc.com.cn/EN/Y2014/V08/I02/109

Figures/Tables 3

组别	例数	CD68( $\bar{x}$ ±s)	Bcl-2( $\bar{x}$ ±s)	VEGF165( $\bar{x}$ ±s)
乳腺癌组织	40	42 577.08±13 048.37	53 137.35±15 361.48	42 272.25±7615.99
癌旁组织	40	8172.51±2504.49	21 688.71±6269.99	12 966.95±2336.19
t值		20.637	21.877	35.104
P值		0.000	0.000	0.000

组别	例数	CD68( $\bar{x}$ ±s)	Bcl-2( $\bar{x}$ ±s)	VEGF165( $\bar{x}$ ±s)
乳腺癌组织	40	42 577.08±13 048.37	53 137.35±15 361.48	42 272.25±7615.99
癌旁组织	40	8172.51±2504.49	21 688.71±6269.99	12 966.95±2336.19
t值		20.637	21.877	35.104
P值		0.000	0.000	0.000

临床病理参数	例数	CD68表达			Bcl-2表达			VEGF165表达
临床病理参数	例数	阳性(例)	检验值	P值	阳性(例)	检验值	P值	阳性(例)	检验值	P值
年龄
≤60岁	25	18	0.000	1.000	20	0.010^b	0.922	20	0.000^b	1.000
＞60岁	15	10	0.000	1.000	11	0.010^b	0.922	12	0.000^b	1.000
转移淋巴结
无	15	6	8.127	0.004	8	5.974^b	0.015	9		0.036^a
有	25	22	8.127	0.004	23	5.974^b	0.015	23		0.036^a
TNM分期
Ⅰ+Ⅱ期	25	14	4.571	0.033	17	4.167	0.041	17	4.167	0.041
Ⅲ+Ⅳ期	15	14	4.571	0.033	15	4.167	0.041	15	4.167	0.041
脉管癌栓
无	37	25		0.541^a	28		1.000^a	29		1.000^a
有	3	3		0.541^a	3		1.000^a	3		1.000^a
ER
阴性	12	8	0.000	1.000	9	0.000	1.000	10		1.000^a
阳性	28	20	0.000	1.000	22	0.000	1.000	22		1.000^a
PR
阴性	19	11	1.547^b	0.214	13		0.265^a	14		0.442^a
阳性	21	17	1.547^b	0.214	18		0.265^a	18		0.442^a

References 15

[1]	Wu H, Xu JB, He YL, et al. Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer[J]. J Surg Oncol,2012,106(4): 462-468.
[2]	Ma Y, Ma L, Guo Q, et al. Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients[J]. J Exp Clin Cancer Res,2010 30(29): 85-90.
[3]	张绘宇, 张雅洁. 非小细胞肺癌生物学特性免疫组化图像定量分析[J].中国体视学与图像分析,2006,11(2): 77-79.
[4]	Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection[J]. Cancer Lett,2008,267(2): 204-215.
[5]	Murdoch C, Giannoudis A, Lewis CE, et al. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues[J]. Blood,2004,104(8): 2224-2234.
[6]	宋瑞卉, 张宝刚, 李洪利,等.肿瘤相关巨噬细胞通过EMT促进乳腺癌的浸润转移[J]. 中国细胞生物学学报, 2013,35(5): 1-6.
[7]	Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis[J]. Radiother Oncol,2011,100(1): 22-32.
[8]	Wouters A, Pauwels B, Lardon F, et al. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions[J]. Oncologist,2007,12(6): 690-712.
[9]	Minet E, Michel G, Remacle J, et al. Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis(review) [J]. Int J Mol Med,2000,5(3): 253-259.
[10]	Shang ZJ, Li ZB, Li JR. VEGF is up-regulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: in vitro and in vivo studies[J]. Int J Oral Maxillofac Surg,2006,35(6): 533-538.
[11]	Poon RT, Fan ST, Wong J, et al. Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and the rapeutic approaches [J]. Ann Surg, 2003,238(1): 9-28.
[12]	Lewis JS, Landers RJ, Underwood JC, et al. Expression of vascular endothelial growth factor by macrophages is upregulated in poorly vascularized areas of breast carcinomas[J].J Pathol,2000,192(2): 150-158.
[13]	盛世乐, 黄钢. VEGF 上调survivin 和bcl-2 表达及抑制乳腺癌细胞凋亡的机制探讨[J]. 肿瘤,2005,25(6): 525-529.
[14]	Krause S, Förster Y, Kraemer K, et al. Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C,gemcitabine and Cisplatin[J]. J Urol,2005,174(1): 328-331.
[15]	Kaneko T,Zhang Z,Mantellini MG,et al. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth[J]. Cancer Res,2007,67(20): 9685-9693.

Please choose a citation manager

Content to export